Contact
searchSearch
HMP Global
Login

Journal of Clinical Pathways

From the Journal

From the Field
Shining a Light on Payer Management in Medical-Benefit Oncology: A Call for Action to Prioritize Patient Care
04/18/2026
Lucio Gordan, MD; Kiana Mehring, MBA, PPMC; David T. Wenk, MD; Josh Eaves; Ryan Ciarrocchi
This study reveals how increasing payer control over oncology treatments is driving delays and administrative burden, undermining evidence-based, physician-led care and timely patient access.
This study reveals how increasing payer control over oncology treatments is driving delays and administrative burden, undermining evidence-based, physician-led care and timely patient access.
This study reveals how...
04/18/2026
Journal of Clinical Pathways
Original Research
NALIRIFOX Compared With FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma: An Overall Survival External Control Arm Study
04/18/2026
Daniel A. King, MD, PhD; Mei Sheng Duh, ScD; Rose Chang, ScD; Louise Yu, MS; Chunyi Xu, MS; Eric M. Maiese, PhD; George Kim, MD
This study highlights NALIRIFOX as a potentially more effective first-line treatment than FOLFIRINOX for treatment-naive metastatic pancreatic ductal adenocarcinoma.
This study highlights NALIRIFOX as a potentially more effective first-line treatment than FOLFIRINOX for treatment-naive metastatic pancreatic ductal adenocarcinoma.
This study highlights NALIRIFOX...
04/18/2026
Journal of Clinical Pathways
Original Research
Clinical Pathways to Address Racial Disparities in Uterine Cancer: A SEER-Based Needs Analysis
02/19/2026
Alexandrina Balanean, MPH, MWC; Yolaine J. Jeune-Smith, PhD; Parisa Asgarisabet, PhD, MBA; Camryn Craig, BS; Harlen Hays, MPH; JaLyna Laney, RN, OCN; Ajeet Gajra, MD, FACP; Bruce A. Feinberg, DO
Evidence from a national cohort study highlights significant survival and treatment disparities among patients with uterine cancer, pointing to clinical pathways as a potential strategy to advance equity and improve outcomes.
Evidence from a national cohort study highlights significant survival and treatment disparities among patients with uterine cancer, pointing to clinical pathways as a potential strategy to advance equity and improve outcomes.
Evidence from a national cohort...
02/19/2026
Journal of Clinical Pathways
Original Research
Bispecific Antibody Treatments for Multiple Myeloma: A Hybrid Academic-Community Cancer Center’s Outpatient Step-up Dosing Care Model
02/17/2026
Christopher J. Ferreri, MD; Peter M. Voorhees, MD; Marvin Knight; Meaghan Roach, MPH; Richard Murphy, BA; Amal Jamaleddine, BA; Nicole Bariahtaris, BA; Cindy Varga, MD
This study demonstrates how a Hospital-at-Home–supported outpatient model can safely deliver step-up dosing of teclistamab and talquetamab for selected patients with relapsed/refractory multiple myeloma.
This study demonstrates how a Hospital-at-Home–supported outpatient model can safely deliver step-up dosing of teclistamab and talquetamab for selected patients with relapsed/refractory multiple myeloma.
This study demonstrates how a...
02/17/2026
Journal of Clinical Pathways
Original Research
Outpatient Care Model for Teclistamab Step-Up Dosing for the Treatment of Relapsed or Refractory Multiple Myeloma at OneOncology: Insights From a Managed Network of Independent Physician-Owned Community-Based Oncology Practices
12/15/2025
Lisa Raff, PharmD; Rozanne Wilson, PhD; Richard Murphy, BA; Amal Jamaleddine, BA; Nicole Bariahtaris, BA; Meaghan Roach, MPH
A community-derived playbook from OneOncology outlines practical strategies for delivering teclistamab step-up dosing in outpatient settings, enabling safer, more convenient access for patients.
A community-derived playbook from OneOncology outlines practical strategies for delivering teclistamab step-up dosing in outpatient settings, enabling safer, more convenient access for patients.
A community-derived playbook...
12/15/2025
Journal of Clinical Pathways
Original Research
Immunotherapy at the End of Life
12/15/2025
Gagandeep Kaur, DO; Havi Rosen, MD; Luke Shenton, MD; Terrence Sun, DO; Abigail Mackenzie, MD; Leah Puglisi, MS; Catherine Weir, DO; Marin Feldman Xavier, MD; Diana Vesselinovitch Maslov, MD
This retrospective study of patients treated with immune checkpoint inhibitors highlights cancer-specific patterns of end-of-life use, the risks and timing of immune-related adverse events, and the critical need for patient-centered...
This retrospective study of patients treated with immune checkpoint inhibitors highlights cancer-specific patterns of end-of-life use, the risks and timing of immune-related adverse events, and the critical need for patient-centered...
This retrospective study of...
12/15/2025
Journal of Clinical Pathways
Original Research
Standardizing Somatic and Germline Molecular Testing in Prostate Cancer: Care Pathway and EHR Applications
10/15/2025
Mehmet Asim Bilen, MD; Aleksandar Zafirovski, MBA; Robert A. Bailey, MD; Ibrahim Khilfeh, PharmD; Urmi Bapat, MD; Kyra Svoboda, BS; Michael Kramer, MD, MBA
This study presents the development of an evidence-informed care pathway and EHR-integrated tools to standardize tumor and germline testing workflows for patients with metastatic prostate cancer.
This study presents the development of an evidence-informed care pathway and EHR-integrated tools to standardize tumor and germline testing workflows for patients with metastatic prostate cancer.
This study presents the...
10/15/2025
Journal of Clinical Pathways
Original Research
Real-World Outcomes of Next-Generation Sequencing of Progressive Radioactive Iodine Refractory Metastatic Thyroid Cancer and Treatment of These Patients With Redifferentiation Protocol
10/15/2025
Jennifer Wheeley, MS, FNP-C; Nikita Chintapally, MD; Kanchan Kulkarni, MD; Gabriel Yohe, MS; Priya Kundra, MD; Jennifer Rosen, MD; Muhammad M. Shaikh, MD; Meeta Sharma, MD; Jason Wexler, MD; Kenneth D. Burman, MD; Leila Shobab, MD; Irina Veytsman, MD
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted...
10/15/2025
Journal of Clinical Pathways
From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2025
Anna Bolha, MPAS, PA; Rebecca Maniago, PharmD, BCOP; Nina Sardesh; Taylor Dias-Foundas; James Roose, MA; Colin Harvey; Marcello Ricottone; Eric Weber; Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC; Brian Patrick Mulherin, MD; Andrew Hertler, MD, FACP; James Hamrick, MD, MPH
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2025
Journal of Clinical Pathways
From the Field
Operationalizing Weight-Based Dosing of Pembrolizumab: Opportunities and Challenges
08/15/2025
Samyukta Mullangi, MD, MBA; Alphan Kirayoglu, MA; Amila Patel, PharmD; Robert J. Green, MD, MSCE; Keshav Goel, MS; James Gilmore, PharmD; Stephen Garrel Divers, MD
To curb the high cost of cancer care driven by flat-dose pricing of drugs like pembrolizumab, the American Oncology Network has implemented a suite of technological and workflow innovations that increased weight-based dosing, offering a...
To curb the high cost of cancer care driven by flat-dose pricing of drugs like pembrolizumab, the American Oncology Network has implemented a suite of technological and workflow innovations that increased weight-based dosing, offering a...
To curb the high cost of cancer...
08/15/2025
Journal of Clinical Pathways

KOL Insights

Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways

In the News

News
Frailty Predicts Fewer Days at Home After Ovarian Cancer Surgery
06/17/2026
Hannah Musick
Frailty—not age alone—was the strongest predictor of reduced time spent alive and at home during the year after ovarian cancer surgery, with frail older adults experiencing substantially worse long-term recovery and higher mortality than...
Frailty—not age alone—was the strongest predictor of reduced time spent alive and at home during the year after ovarian cancer surgery, with frail older adults experiencing substantially worse long-term recovery and higher mortality than...
Frailty—not age alone—was the...
06/17/2026
Journal of Clinical Pathways
News
HCC Surveillance Rates Declined During COVID-19 and Remain Low in the Post-Pandemic Era
06/16/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) surveillance decreased during the COVID-19 pandemic, and rates have not yet rebounded to pre-pandemic levels, sparking concern among researchers and calling for a need to expand care access and implement...
Hepatocellular carcinoma (HCC) surveillance decreased during the COVID-19 pandemic, and rates have not yet rebounded to pre-pandemic levels, sparking concern among researchers and calling for a need to expand care access and implement...
Hepatocellular carcinoma (HCC)...
06/16/2026
Journal of Clinical Pathways
News
High-Volume Facilities Are Linked to Improved Survival Outcomes for Patients With MM
06/09/2026
Rebecca Amrick
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are...
06/09/2026
Journal of Clinical Pathways
News
Telemedicine Expansion Not Associated With Higher Health Care Utilization or Costs
06/08/2026
Rebecca Amrick
Analyzing data from MedInsight, researchers found no significant association between telemedicine adoption and care utilization and spending, alleviating worries about the impact of telemedicine expansion on the US health care system.
Analyzing data from MedInsight, researchers found no significant association between telemedicine adoption and care utilization and spending, alleviating worries about the impact of telemedicine expansion on the US health care system.
Analyzing data from MedInsight,...
06/08/2026
Journal of Clinical Pathways
News
Geographic Distribution Creates Disparities in Access to MM CAR T Care Centers
06/03/2026
Rebecca Amrick
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of...
06/03/2026
Journal of Clinical Pathways
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways
News
Evolving Treatment Patterns in HCC Reflect Expanding Role of Immunotherapy
05/27/2026
Rebecca Amrick
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving...
05/27/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Guideline-Based Pathways Could Streamline Prior Authorization Processes
05/21/2026
Rebecca Amrick
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have...
05/21/2026
Journal of Clinical Pathways
News
Higher Radon Levels Connected to Increased Risk of Ovarian Cancer in Postmenopausal Women
05/21/2026
Rebecca Amrick
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds...
05/21/2026
Journal of Clinical Pathways

Quality Outlook

Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Quality Outlook
Every Second Counts: the Impact of FDA’s Accelerated Approval Program
03/05/2025
Bridget Doherty, MPH, MS; Silas Martin, MS; Tom Valuck, MD, JD
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research...
03/05/2025
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
Winston Wong, PharmD
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Kendall Logan, MPH.
Quality Outlook
A Tale of Two States: Examining the Best and Worst Performing States for HPV Vaccination
02/12/2024
Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther; Tom Valuck, MD, JD
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a three-part series exploring the disparities related to human papilloma virus (HPV) vaccination rates in the US.
This blog post is the last in a...
02/12/2024
Journal of Clinical Pathways
Theresa Schmidt headshot.
Quality Outlook
2024 Quality Outlook Revealed: Insights from 2023 Fall Conferences
02/02/2024
Tom Valuck, MD, JD; Erik Muther; Theresa Schmidt, MA, PMP, CSPO; Danny Bellet, MBA; Donna Dugan, PhD, MS; David Sloan, PhD
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the...
02/02/2024
Journal of Clinical Pathways
Anne Disalvo headshot
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Racial and Ethnic Disparities in HPV Vaccination
11/10/2023
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a...
11/10/2023
Journal of Clinical Pathways
Anne DiSalvo.
Quality Outlook
Saving Lives from Preventable Cancer: Solutions for Geographic Disparities in HPV Vaccination
10/03/2023
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part...
10/03/2023
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use